Aimsco

Aimsco is a United Kingdom-based biotechnology company focused on the development and production of Aimspro, a hyperimmune caprine (goat) serum. This polyclonal antibody therapy is designed to treat a variety of inflammatory and neurological conditions by modulating the immune response and neutralizing pro-inflammatory cytokines. The company operates its own specialized manufacturing facility to produce the serum from immunized goats under controlled conditions. While Aimspro has been investigated in several clinical trials for indications such as Multiple Sclerosis and Amyotrophic Lateral Sclerosis, the company has faced a complex regulatory environment in the UK. Aimsco continues to seek pathways for the clinical advancement and broader availability of its lead therapeutic candidate.